Researcher Profiles

Return to member profile

Janice M. Mehnert, MD

Publications since 2011

Spencer, K. R. Mehnert, J. M. Mucosal Melanoma: Epidemiology, Biology and Treatment. Cancer Treat Res, 167:295-320, . (PMID: 26601869)

Spencer, K. R. Mehnert, J. M. Importance of including patients with comorbidities in clinical trials. Lancet Oncol, 17:17-18, . (PMID: 26758750)

Johnson, D. B. Sullivan, R. J. Ott, P. A. Carlino, M. S. Khushalani, N. I. Ye, F. Guminski, A. Puzanov, I. Lawrence, D. P. Buchbinder, E. I. Mudigonda, T. Spencer, K. Bender, C. Lee, J. Kaufman, H. L. Menzies, A. M. Hassel, J. C. Mehnert, J. M. Sosman, J. A. Long, G. V. Clark, J. I. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol, In process, . (PMID: 26633184)

White, E. Mehnert, J. M. Chan, C. S. Autophagy, Metabolism, and Cancer. Clin Cancer Res, 21:5037-5046, . (PMID: 26567363, PMCID: PMC4646728)

Stein, M. N. Hussain, M. Stadler, W. M. Liu, G. Tereshchenko, I. V. Goodin, S. Jeyamohan, C. Kaufman, H. L. Mehnert, J. DiPaola, R. S. A Phase II Study of AT-101 to Overcome Bcl-2-Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. Clin Genitourin Cancer, In process, . (PMID: 26476589)

Goyal, S. Silk, A. W. Tian, S. Mehnert, J. Danish, S. Ranjan, S. Kaufman, H. L. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. JAMA Oncol, In process, . (PMID: 26181286)

Higano, C. S. Berlin, J. Gordon, M. LoRusso, P. Tang, S. Dontabhaktuni, A. Schwartz, J. D. Cosaert, J. Mehnert, J. M. Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors. Invest New Drugs, 33:450-462, . (PMID: 25749986)

Dharmadhikari, N. Mehnert, J. M. Kaufman, H. L. Oncolytic virus immunotherapy for melanoma. Curr Treat Options Oncol, 16:326, . (PMID: 25777572)

Mehnert, J. M. Xie, X. Koh, J. Y. Price, S. White, E. Atg7 overcomes senescence and promotes growth of BRAFV600E-driven melanoma. Cancer Discov, In process, . (PMID: 25673642)

Teh, J. L. Shah, R. Shin, S. S. Wen, Y. Mehnert, J. M. Goydos, J. Chen, S. Metabotropic glutamate receptor 1 (mGluR1) mediates melanocyte transformation via transactivation of IGF-1 Receptor. Pigment Cell Melanoma Res, 27:621-629, . (PMID: 24628914, PMCID: PMC4061214)

Wen, Y. Y. Li, J. Koo, J. Shin, S. S. Lin, Y. Jeong, B. S. Mehnert, J. M. Chen, S. Cohen-Solal, K. Goydos, J. S. Activation of the Glutamate Receptor GRM1 Enhances Angiogenic Signaling to Drive Melanoma Progression. Cancer Res, 74:2499-2509, . (PMID: 24491800, PMCID: PMC4008638)

Salgia, R. Patel, P. Bothos, J. Yu, W. Eppler, S. Hegde, P. Bai, S. Kaur, S. Nijem, I. Catenacci, D. V. Peterson, A. Ratain, M. J. Polite, B. Mehnert, J. M. Moss, R. A. Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clin Cancer Res, 20:1666-1675, . (PMID: 24493831)

Palyca, P. Koshenkov, V. P. Mehnert, J. M. Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need. Am Soc Clin Oncol Educ Book, :e397-e404, . (PMID: 24857130)

Ravi, S. Spencer, K. Ruisi, M. Ibrahim, N. Luke, J. J. Thompson, J. A. Shirai, K. Lawson, D. Bartell, H. Kudchadkar, R. Gunter, N. T. Mehnert, J. M. Lipson, E. J. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer, 2:33, . (PMID: 25317333, PMCID: PMC4195895)

Sharma, A. Thompson, J. A. Repaka, A. Mehnert, J. M. Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. J Clin Oncol, 31:e370-e372, . (PMID: 23775956)

Xie, X. White, E. P. Mehnert, J. M. Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma. PLoS One, 8:e55096, . (PMID: 23383069, PMCID: PMC3559441)

Mehnert, J. M. Kluger, H. M. Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies. Curr Oncol Rep, 14:449-457, . (PMID: 22723080)

Saraiya, B. Chugh, R. Karantza, V. Mehnert, J. Moss, R. A. Savkina, N. Stein, M. N. Baker, L. H. Chenevert, T. Poplin, E. A. Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. Invest New Drugs, 30:258-265, . (PMID: 20697775)

Patel, A. N. Mehnert, J. M. Kim, S. Treatment of recurrent metastatic head and neck cancer: focus on cetuximab. Clin Med Insights Ear Nose Throat, 5:1-16, . (PMID: 24179404, PMCID: PMC3791949)

Mehnert, J. M. Tan, A. R. Moss, R. Poplin, E. Stein, M. N. Sovak, M. Levinson, K. Lin, H. Kane, M. Gounder, M. Lin, Y. Shih, W. J. White, E. Rubin, E. H. Karantza, V. Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. Mol Cancer Ther, 10:1509-1519, . (PMID: 21680752, PMCID: PMC3155243)

Khan, A. J. Wall, B. Ahlawat, S. Green, C. Schiff, D. Mehnert, J. M. Goydos, J. S. Chen, S. Haffty, B. G. Riluzole Enhances Ionizing Radiation-Induced Cytotoxicity in Human Melanoma Cells that Ectopically Express Metabotropic Glutamate Receptor 1 In Vitro and In Vivo. Clin Cancer Res, 17:1807-1814, . (PMID: 21325066, PMCID: PMC3070864)